Type Whole antibody ATC code none IUPHAR/BPS 7785 | CAS Number 1085337-57-0 | |
Target GM-CSF receptor alpha chain | ||
Mavrilimumab is a human monoclonal antibody that inhibits human granulocyte macrophage colony-stimulating factor receptor (GM-CSF-R).
Mavrilimumab was discovered as CAM-3001 by Cambridge Antibody Technology and is being developed by MedImmune, Inc. as an investigational drug for the treatment of rheumatoid arthritis
Mavrilimumab has been studied in a phase 1 dose-ranging trial and a phase 2a clinical trial, both sponsored by Medimmune. The phase 2a trial, which studied mavrilimumab doses of up to 100 mg, reported that 55.7% of subjects met the primary endpoint of a ≥1.2 decrease from baseline in disease activity scores at week 12 (vs. only 34.7% of placebo subjects).
As of 2013, two further clinical studies were reported to be underway in rheumatoid arthritis patients to investigate these effects further.
In early 2017 the EARTH EXPLORER 1 phase IIb study was reported to be showing promising results.